-
公开(公告)号：US4862886A
公开(公告)日：1989-09-05
申请号：US731961
申请日：1985-05-08
CPC分类号： G02B6/4296 , A61B18/245 , A61B2017/00154 , A61B2017/00194 , A61B2017/22051 , A61B90/39 , G02B2006/4297
摘要： A laser therapy system having improved effectiveness in surgical use, particularly in laser angioplasty, can be formed by employing a pulsed source of radiation. The pulsed energy source is preferably an excimer laser having a coherent beam of ultraviolet radiation and preferably is employed in conjunction with a dye laser to produce an output beam which is tunable over a wide portion of the ultraviolet and visible spectrum. The output beam is coupled via a novel coupling device to an optical fiber disposed within a surgical instrument, for example, a percutaneous catheter. The operative components are sealed in a gas-tight, liquid-tight housing. An electronic controller monitors and adjusts the output energy density, duration, and pulse repetition rate. In operation, a pulsed, high energy beam of extremely short duration is available to remove atherosclerotic plague with less damage to the underlying tissue and less chance of perforating the blood vessel wall.
摘要翻译： 可以通过采用脉冲辐射源形成具有改善的外科用途有效性的激光治疗系统，特别是在激光血管成形术中。 脉冲能量源优选是具有相干紫外线辐射束的准分子激光器，并且优选与染料激光器结合使用以产生可在紫外线和可见光谱的宽部分上调节的输出光束。 输出光束通过新颖的耦合装置耦合到设置在外科器械例如经皮导管内的光纤。 操作部件密封在气密，液密的外壳中。 电子控制器监视和调整输出能量密度，持续时间和脉冲重复率。 在操作中，具有极短持续时间的脉冲的高能量束可用于以较少的对下面的组织的损伤去除动脉粥样硬化性瘟疫并且具有较小的穿孔血管壁的机会。
-
公开(公告)号：US07125856B1
公开(公告)日：2006-10-24
申请号：US09546733
申请日：2000-04-11
申请人： Jeffrey M. Isner
发明人： Jeffrey M. Isner
CPC分类号： A61K31/70
摘要： A method for treating peripheral neuropathy, particularly ischemic peripheral neuropathy, is provided. The method involves administering to subjects in need of such treatment an effective amount of an angiogenic growth factor to alleviate a symptom of the neuropathy.
摘要翻译： 提供了治疗周围神经病变，特别是缺血性周围神经病变的方法。 该方法包括对需要这种治疗的受试者施用有效量的血管生成生长因子以减轻神经病变的症状。
-
3.发明授权
公开(公告)号：US5851521A
公开(公告)日：1998-12-22
申请号：US723726
申请日：1996-09-30
IPC分类号： C12N15/09 , A61K9/10 , A61K35/76 , A61K38/00 , A61K48/00 , A61P9/00 , A61P43/00 , C07K14/47 , C12N7/00 , C12N7/01 , C12N15/63 , C12N15/86
CPC分类号： C07K14/4703 , A61K38/00 , A61K48/00 , C12N2799/022
摘要： The present invention relates to replication defective recombinant viruses which contain at least one inserted gene encoding all or part of the protein GAX or of a variant of this protein, and to their therapeutic use, in particular for treating post-angioplastic restenosis.
-
公开(公告)号：US06676937B1
公开(公告)日：2004-01-13
申请号：US09265041
申请日：1999-03-09
申请人： Jeffrey M. Isner , Takayuki Asahara
发明人： Jeffrey M. Isner , Takayuki Asahara
IPC分类号： A01N6300
CPC分类号： G01N33/56972 , A61K35/44 , A61K38/1866 , A61K38/193 , A61K2300/00
摘要： The present invention generally provides methods for modulating formation of new blood vessels. In one embodiment, the methods include administering to a mammal an effective amount of granulocyte macrophage-colony stimulating factor (GM-CSF) sufficient to form the new blood vessels. Additionally provided are methods for preventing or reducing the severity of blood vessel damage in a mammal which methods preferably include administering to the mammal an effective amount of GM-CSF. Provided also as part of this invention are pharmaceutical products and kits for inducing formation of new blood vessels in the mammal.
摘要翻译： 本发明一般提供调节新血管形成的方法。 在一个实施方案中，所述方法包括向哺乳动物施用足以形成新血管的有效量的粒细胞巨噬细胞集落刺激因子（GM-CSF）。 另外提供了用于预防或降低哺乳动物血管损伤的严重性的方法，其中优选包括向哺乳动物施用有效量的GM-CSF。 还提供作为本发明的一部分的是用于在哺乳动物中诱导新血管形成的药物产品和试剂盒。
-
公开(公告)号：US06258787B1
公开(公告)日：2001-07-10
申请号：US08910539
申请日：1997-07-30
申请人： Jeffrey M. Isner
发明人： Jeffrey M. Isner
IPC分类号： A01N4304
CPC分类号： C07K14/52 , A61K38/1866 , A61K48/00
摘要： The present invention provides a method for inducing reendothelialization of the lining of an injured blood vessel comprising contacting the injured portion of the vessel with nucleic acid encoding an endothelial cell mitogen operably linked to a promoter (nucleic acid cassette) to result in expression of the mitogen when delivered to the cells at the site of vascular injury. The resulting reendothelialization of the injured blood vessel inhibits smooth muscle cell proliferation and consequently reduces restenosis. The methods of the present invention may be used to treat any blood vessel injury that results in denuding of the endothelial lining of the vessel wall, including, for example, those injuries resulting from balloon angioplasty and deployment of endovascular stents.
摘要翻译： 本发明提供了一种用于诱导受损血管的内衬的内皮形成的方法，包括使损伤的血管部分与编码与启动子（核酸盒）可操作连接的内皮细胞丝裂原的核酸接触，以导致丝裂原的表达 当被传送到血管损伤部位的细胞时。 受伤血管的内皮形成导致平滑肌细胞增殖，从而减少再狭窄。 本发明的方法可用于治疗导致血管壁内皮衬里剥蚀的任何血管损伤，包括例如球囊血管成形术和血管内支架部署引起的损伤。
-
公开(公告)号：US4997431A
公开(公告)日：1991-03-05
申请号：US400702
申请日：1989-08-30
申请人： Jeffrey M. Isner , Richard Clarke
发明人： Jeffrey M. Isner , Richard Clarke
CPC分类号： A61B18/245 , A61N1/057 , A61B2017/3488 , A61B2018/00011 , A61B90/39 , A61M2025/0098
摘要： A technique for percutaneous treatment of idiopathic hypertropic subaortic stenosis (IHSS) and hypertrophic cardiomyopathy (HCM). IHSS and HCM are diseases of the heart in which the septum of the left ventricle thickens resulting in reduced ventricular performance. Current treatments involve drug therapy or a medical intervention called an interoperative myotomy/myectomy using the Morrow procedure. The present invention uses laser energy delivered via fiber optics placed percutaneously to irradiate the thickened septum to reduce tissue volume of the septum and enhance left ventricular function.
摘要翻译： 一种经皮治疗特发性高血压主动脉瓣狭窄（IHSS）和肥大型心肌病（HCM）的技术。 IHSS和HCM是心脏的疾病，其中左心室的隔膜增厚，导致心室表现降低。 目前的治疗包括药物治疗或称为术中肌间切除术/肌层切除术的医学干预，使用Morrow手术。 本发明使用通过经由光纤放置的激光能量照射增厚的隔膜以减少隔膜的组织体积并增强左心室功能。
-
公开(公告)号：US06569428B1
公开(公告)日：2003-05-27
申请号：US09228020
申请日：1999-01-11
申请人： Jeffrey M. Isner , Takayuki Asahara
发明人： Jeffrey M. Isner , Takayuki Asahara
IPC分类号： A61K3512
CPC分类号： A61K45/06 , A61K48/00 , A61K2035/124 , C12N5/0691 , C12N5/0692 , C12N2510/00
摘要： Pharmaceutical products are provided comprising EC progenitors for use in methods for regulating angiogenesis, i.e., for enhancing or inhibiting blood vessel formation, in a selected patient and in some preferred embodiments for targeting an angiogenesis modulator to specific locations. For example, the EC progenitors can be used to enhance angiogenesis or to deliver an angiogenesis modulator, e.g., anti- or pro-angiogenic agents, respectively to sites of pathologic or utilitarian angiogenesis. Additionally, in another embodiment, EC progenitors can be used to induce reendothelialization of an injured blood vessel, and thus reduce restenosis by indirectly inhibiting smooth muscle cell proliferation.
摘要翻译： 提供的药物产品包括用于调节血管生成的方法的EC祖细胞，即用于增强或抑制所选择的患者中的血管形成，以及用于将血管生成调节剂靶向特定位置的一些优选实施方案。 例如，EC祖细胞可用于增强血管发生或将血管生成调节剂例如抗血管生成剂或促血管生成剂分别递送至病理或功能性血管发生部位。 此外，在另一个实施方案中，EC祖细胞可用于诱导受损血管的内皮形成，并因此通过间接抑制平滑肌细胞增殖来减少再狭窄。
-
8.再颁专利Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis 有权病毒载体及其用于治疗过度增殖性疾病，特别是再狭窄的用途公开(公告)号：USRE37933E1
公开(公告)日：2002-12-10
申请号：US09740876
申请日：2000-12-21
IPC分类号： A61K3576
CPC分类号： C07K14/4703 , A61K38/00 , A61K48/00 , C12N2799/022
摘要： The present invention relates to replication defective recombinant viruses which contain at least one inserted gene encoding all or part of the protein GAX or of a variant of this protein, and to their therapeutic use, in particular for treating post-angioplastic restenosis.
摘要翻译： 本发明涉及复制缺陷型重组病毒，其含有编码全部或部分蛋白质GAX或该蛋白质的变体的至少一个插入基因及其治疗用途，特别是用于治疗血管再生后再狭窄。
-
公开(公告)号：US5830879A
公开(公告)日：1998-11-03
申请号：US538301
申请日：1995-10-02
申请人： Jeffrey M. Isner
发明人： Jeffrey M. Isner
IPC分类号： A61M25/00 , A61K38/18 , A61K38/19 , A61K48/00 , C07K14/52 , A01N43/04 , A61K31/70 , C12N15/63
CPC分类号： C07K14/52 , A61K38/1866 , A61K48/00
摘要： The present invention provides a method for inducing reendothelialization of the lining of an injured blood vessel comprising contacting the injured portion of the vessel with nucleic acid encoding an endothelial cell mitogen such as vascular endothelial growth factor (VEGF) operably linked to a promoter to result in expression of the mitogen when delivered to the cells at the site of vascular injury. The resulting reendothelialization of the injured blood vessel inhibits smooth muscle cell proliferation and consequently reduces restenosis. The methods of the present invention may be used to treat any blood vessel injury that results in denuding of the endothelial lining of the vessel wall, including, for example, those injuries resulting from balloon angioplasty and deployment of endovascular stents.
摘要翻译： 本发明提供了一种诱导损伤血管的内衬的内皮形成的方法，包括使损伤的血管部分与编码内皮细胞丝裂原的核酸（例如可操作地连接到启动子的血管内皮生长因子（VEGF））接触，导致 当在血管损伤部位递送至细胞时有丝分裂原的表达。 受伤血管的内皮形成导致平滑肌细胞增殖，从而减少再狭窄。 本发明的方法可用于治疗导致血管壁内皮衬里剥蚀的任何血管损伤，包括例如球囊血管成形术和血管内支架部署引起的损伤。
-
公开(公告)号：US5652225A
公开(公告)日：1997-07-29
申请号：US675523
申请日：1996-07-03
申请人： Jeffrey M. Isner
发明人： Jeffrey M. Isner
CPC分类号： A61L27/36
摘要： The present invention provides a method for the delivery of a nucleic acid to an arterial cell comprising contacting the cell with a hydrophilic polymer incorporating the nucleic acid. The nucleic acid may be any nucleic acid, including antisense DNA or RNA. The nucleic acid may encode hormones, enzymes, receptors or drugs of interest. The nucleic acid is selected based upon the desired therapeutic outcome. For example, in the treatment of ischemic diseases, one would select a DNA encoding an angiogenic protein. The nucleic acid may be carried by a microdelivery vehicle such as cationic liposomes and adenoviral vectors. DNA encoding different proteins may be used separately or simultaneously.
摘要翻译： 本发明提供了将核酸递送至动脉细胞的方法，包括使细胞与掺入核酸的亲水性聚合物接触。 核酸可以是任何核酸，包括反义DNA或RNA。 核酸可以编码激素，酶，受体或感兴趣的药物。 基于所需的治疗结果选择核酸。 例如，在缺血性疾病的治疗中，可以选择编码血管生成蛋白的DNA。 核酸可以由微递送载体如阳离子脂质体和腺病毒载体携带。 编码不同蛋白质的DNA可以单独使用或同时使用。
-
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.026 秒)
